Patent

Growth in drug spending to slow as generics rise

May 18, 2011
Bloomberg News
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
More

Zimmer, peer sued over arthritic-knee treatments

April 26, 2011
Bloomberg News
Genzyme Corp., the drugmaker bought by Sanofi-Aventis SA this month, sued Zimmer Holdings Inc. and Anika Therapeutics Inc. alleging the companies’ treatments for arthritic knee pain infringe a patent.
More

Firm joins race with IU autism drug

April 9, 2011
J.K. Wall
The Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
More

Lechleiter: After the deluge, we'll be fine

March 16, 2011
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
More

Dow Chemical moves toward engineered corn patent

March 1, 2011
Associated Press
Dow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
More

Congress takes up major change in patent law

February 28, 2011
Associated Press
Congress has been trying for well over a decade to rewrite patent law, only to be thwarted by the many interested parties.
More

Intellectual property theft rising quicklyRestricted Content

February 26, 2011
Bob Kronemyer / Special to IBJ
Filching ranges from crude to highly sophisticated, experts say.
More

Emerging markets give Lilly hope in patent crunch

February 19, 2011
J.K. Wall
In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
More

Vanderbilt rejected by high court on Cialis patents

January 24, 2011
Bloomberg News
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly's Icos subsidiary.
More

Eli Lilly puts faith in drug pipeline

December 24, 2010
J.K. Wall
Eli Lilly and Co. started to tip over its massive “patent cliff” this year, yet announced little publicly that will significantly soften its inevitable sales plunge.
More

Hillenbrand wins ban of knockoff coffins from Mexico

December 14, 2010
Bloomberg News
The U.S. International Trade Commission said Monday that Ataudes Aguilares will be barred from bringing in caskets with attached memorabilia compartments, which Batesville-based Hillenbrand has patented.
More

Phase 10 inventor folds in dispute over top-selling card game

November 22, 2010
Cory Schouten
The inventor of the world's second-best-selling card game has settled a lawsuit with Fundex Games, the Plainfield company that markets and distributes Phase 10.
More

Lilly scores series of small victories

November 17, 2010
J.K. Wall
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
More

Court upholds Lilly patent on cancer drug Alimta

November 16, 2010
 IBJ Staff and Associated Press
A U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of patent expirations in coming years.
More

Appeals court rejects Lilly over Gemzar patent

November 1, 2010
 IBJ Staff and Bloomberg News
Without an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
More

Appeals court ruling upholds Lilly's Evista patents

September 1, 2010
Bloomberg News
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
More

Lilly braces for plunge in profits

August 14, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of loss of revenue that it's hard to picture what the company will look like in five years.
More

Eli Lilly loses patent lawsuit for Strattera

August 13, 2010
 IBJ Staff and Associated Press
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More

Roche hit with new breed of patent suit

August 11, 2010
J.K. Wall
Roche Diagnostics, a Swiss company that keeps its U.S. headquarters in Indianapolis, has been sued for marking its Accu-Chek blood glucose monitors and accessories with patents that are expired. Illinois resident David O’Neill has sued on behalf of the U.S. government to recover damages of $500 per infraction.
More

Court defeat lost in Lilly's gloomy long-term outlook

August 9, 2010
J.K. Wall
Eli Lilly and Co.'s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn from investors, who have shunned the stock because of five looming patent expirations.
More

Hoosier firms that rely on innovation pine for patent reform

June 26, 2010
J.K. Wall
One key change would grant patents to the first inventor to file an application, not the first who can prove to have made the invention first.
More

Hillenbrand unit seeks to block imports of knockoff coffins

June 11, 2010
Bloomberg News
Hillenbrand Inc.'s Batesville unit, the largest U.S. maker of coffins,wants the trade commission to prevent Ataudes Aguilares from selling its products in the United States and Puerto Rico.
More

Lilly sues to block copy of Evista osteoporosis drug

May 5, 2010
Bloomberg News
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
More

Anderson tech firm One Number files patent suit against GoogleRestricted Content

April 24, 2010
Chris O'Malley
An Anderson firm that provides a “one number” service that rings all of a client’s phones has filed suit against Web giant Google, alleging Google Voice infringes on two of its patents.
More

Noblesville company has high hopes for pomegranate

April 10, 2010
Kathleen McLaughlin
Verdure Sciences, a botanical-extract distributor, has invested more than $1 million in marketing and research, and hopes to see its product in more foods and drinks, perhaps even mouthwash.
More
Page  << 1 2 3 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am also a "vet" of several Cirque shows and this one left me flat. It didn't have the amount of acrobatic stunts as the others that I have seen. I am still glad that I went to it and look forward to the next one but I put Varekai as my least favorite.

  2. Looking at the two companies - in spite of their relative size to one another -- Ricker's image is (by all accounts) pretty solid and reputable. Their locations are clean, employees are friendly and the products they offer are reasonably priced. By contrast, BP locations are all over the place and their reputation is poor, especially when you consider this is the same "company" whose disastrous oil spill and their response was nothing short of irresponsible should tell you a lot. The fact you also have people who are experienced in franchising saying their system/strategy is flawed is a good indication that another "spill" has occurred and it's the AM-PM/Ricker's customers/company that are having to deal with it.

  3. Daniel Lilly - Glad to hear about your points and miles. Enjoy Wisconsin and Illinois. You don't care one whit about financial discipline, which is why you will blast the "GOP". Classic liberalism.

  4. Isn't the real reason the terrain? The planners under-estimated the undulating terrain, sink holes, karst features, etc. This portion of the route was flawed from the beginning.

  5. You thought no Indy was bad, how's no fans working out for you? THe IRl No direct competition and still no fans. Hey George Family, spend another billion dollars, that will fix it.

ADVERTISEMENT